Abbott Laboratories $ABT Shares Acquired by Curio Wealth LLC

Curio Wealth LLC boosted its holdings in Abbott Laboratories (NYSE:ABT) by 15,250.0% during the second quarter, HoldingsChannel reports. The fund owned 307 shares of the healthcare product maker’s stock after buying an additional 305 shares during the period. Curio Wealth LLC’s holdings in Abbott Laboratories were worth $42,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. IMG Wealth Management Inc. grew its holdings in shares of Abbott Laboratories by 759.1% during the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after purchasing an additional 167 shares during the period. Hughes Financial Services LLC purchased a new position in Abbott Laboratories during the first quarter worth about $27,000. Abound Financial LLC purchased a new stake in shares of Abbott Laboratories in the 1st quarter valued at approximately $28,000. Elequin Capital LP acquired a new position in shares of Abbott Laboratories in the 1st quarter worth approximately $30,000. Finally, Vision Financial Markets LLC purchased a new position in shares of Abbott Laboratories during the 1st quarter worth approximately $33,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Trading Up 0.3%

Shares of Abbott Laboratories stock opened at $126.78 on Friday. The company has a fifty day simple moving average of $132.09 and a 200-day simple moving average of $131.61. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The stock has a market cap of $220.65 billion, a price-to-earnings ratio of 15.89, a PEG ratio of 2.41 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. The company had revenue of $11.37 billion during the quarter, compared to the consensus estimate of $11.40 billion. During the same quarter in the prior year, the firm posted $1.21 earnings per share. Abbott Laboratories’s revenue for the quarter was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.9%. Abbott Laboratories’s payout ratio is currently 29.57%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Jefferies Financial Group lifted their price objective on Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research note on Thursday, October 16th. Barclays boosted their price target on shares of Abbott Laboratories from $159.00 to $162.00 and gave the stock an “overweight” rating in a research note on Friday, October 17th. Sanford C. Bernstein upped their target price on shares of Abbott Laboratories from $145.00 to $150.00 and gave the stock an “outperform” rating in a research note on Thursday, October 16th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Abbott Laboratories in a research report on Friday. Finally, The Goldman Sachs Group lifted their target price on Abbott Laboratories from $153.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $147.00.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.